Deuterated drugs; updates and obviousness analysis

References

• Reinhold DF. Processes for asymmetric conversion of 3-fluoro-L-alanine and 2-deutero-3-fluoro-L-alanine to their D-isomers. USPTO 3,950,411. 1976.
   Google Scholar
• McCarty LP. Compositions and methods for anesthetizing an animal using deuterated analogues of halothane and chloroform. USPTO 4,069,346. 1978.
   Google Scholar
• Timmins GS. Deuterated drugs: where are we now? Expert Opin Ther Pat. 2014;24(10):1067–1075.
   PubMed Web of Science ®Google Scholar
• Schmidt C. First deuterated drug approved. Nat Biotechnol. 2017;35:493–494.
   PubMed Web of Science ®Google Scholar
• Frank S, Frank S, Testa CM, et al. Effect of deutetrabenazine on chorea among patients with Huntington disease: a randomized clinical trial. JAMA. 2016;316(1):40–50.
   PubMed Web of Science ®Google Scholar
• Jankovic J, Jimenez-Shahed J, Budman C, et al. Deutetrabenazine in tics associated with Tourette syndrome. Tremor Other Hyperkinet Mov. 2016;6:422.
   Google Scholar
• Anderson KE, Lawrence R, Page E, et al. Addressing involuntary movements in tardive dyskinesia (AIM-TD): effect of fixed-dose deutetrabenazine by baseline comorbidities (S56. 006). Neurology. 2017;88(16 Supplement):S56. 006.
   Google Scholar
• Harbeson SL, Morgan AJ, Liu JF, et al. Altering metabolic profiles of drugs by precision deuteration 2: discovery of a deuterated analog of ivacaftor with differentiated pharmacokinetics for clinical development. J Pharmacol Exp Ther. 2017;362:359–367.
   PubMed Web of Science ®Google Scholar
• Schmidt C. First deuterated drug approved. Nat Research: Nat Biotechnol. 2017;35(6):493–494.
   PubMed Web of Science ®Google Scholar
• Garay RP, Grossberg GT. AVP-786 for the treatment of agitation in dementia of the Alzheimer’s type. Expert Opin Investig Drugs. 2017;26(1):121–132.
   PubMed Web of Science ®Google Scholar
• Garay RP, Zarate CA, Charpeaud T, et al. Investigational drugs in recent clinical trials for treatment-resistant depression. Expert Rev Neurother. 2017;17(6):593–609.
   PubMed Web of Science ®Google Scholar
• Hemphill CS, Sampat BN. Evergreening, patent challenges, and effective market life in pharmaceuticals. J Health Econ. 2012;31(2):327–339.
   PubMed Web of Science ®Google Scholar
• Harbeson SL. Inhibitors of the enzyme udp-glucose: n-acyl-sphingosine glucosyltransferase. USPTO Application 20160068519. 2016.
   Google Scholar
• Masse CE. Deuterated 2-amino-3-hydroxypropanoic acid derivatives. USPTO Application 20160031801. 2016.
   Google Scholar
• Harbeson SL. Deuterated pacritinib. USPTO Application 20160009732. 2016.
   Google Scholar
• Pandya BA, Masse CE, Silverman IR, et al. Derivatives of Pyrazole-Substituted Amino-Heteroaryl Compounds. USPTO Application 20150366853. 2015.
   Google Scholar
• Pandya BA. Deuterated Ponatinib. USPTO Application 20150291594. 2015
   Google Scholar
• Tung RD, Morgan AJ. Deuterated Ibrutinib. USPTO Application 20150210699. 2015.
   Google Scholar
• Tung RD. Deuterated Idebenone. USPTO Application 20150166449. 2015.
   Google Scholar
• Liu JF, Harbeson SL, Tung RD. Pyrazinoisoquinoline compounds. USPTO Application 20150141431. 2015.
   Google Scholar
• Liu JF, Substituted isoindoline-1,3-dione derivatives. USPTO Application 20150105438. 2015.
   Google Scholar
• Tung RD, Morgan AJ, Silverman IR. 4-hydroxybutyric acid analogs. USPTO Application 20140343119. 2014.
   Google Scholar
• Jones AD, Zelle RE, Silverman IR. Synthesis of deuterated catechols and benzo[d][1,3]dioxoles and derivatives thereof. USPTO Application 20140336387. 2014.
   Google Scholar
• Graham PB, Silverman IR. Morphinan compounds. USPTO Application 20140315940. 2014.
   Google Scholar
• Aslanian A, Parasrampuria D, Hogan K, et al. Substituted xanthine derivatives. USPTO Application 20140296263. 2014.
   Google Scholar
• Morgan A. Carbamoylpyridone derivatives. USPTO Application 20140213553. 2014.
   Google Scholar
• Tung R, Masse C, Pandya B. Tetrahydronaphthalene derivatives. USPTO Application 20140155444: USA. 2014.
   Google Scholar
• Harbeson SL. Substituted triazolophthalazine derivatives. USPTO Application 20140024652. 2014,
   Google Scholar
• Tung R, Liu J, Harbeson S. Substituted xanthine derivatives. USPTO Application 20140121226. 2014.
   Google Scholar
• Tung R, Masse CE, Pyrimidine derivatives. USPTO Application 20140018379. 2014,
   Google Scholar
• Pandya B, Masse CE, Silverman IR, et al. Derivatives of pyrazole-substituted amino-heteroaryl compounds. USPTO Application 20140005211. 2014.
   Google Scholar
• Liu F. Substituted isoindoline-1,3-dione derivatives. USPTO Application 20130345282. 2013.
   Google Scholar
• Harbeson SL, Tung R, Liu JF. Substituted triazolo-pyridazine derivatives. USPTO Application 20130317033. 2013.
   Google Scholar
• Harbeson SL. Substituted triazolo-pyridazine derivatives. USPTO Application 20130225590. 2013.
   Google Scholar
• Liu JF, Tung RD. Substituted dioxopiperidinyl phthalimide derivatives. USPTO Application 20130150408. 2013.
   Google Scholar
• Persichetti RA, Liu JF,  Masse CE, et al. Analogues of cilostazol. USPTO Application 20130131021. 2013.
   Google Scholar
• Harbeson SL, Liu JF, Tung R. N-phenyl-2-pyrimidineamine derivatives. USPTO Application 20130121963. 2013.
   Google Scholar
• Persichetti RA, Liu JF. Fluorouracil derivatives. USPTO Application 20130109707. 2013.
   Google Scholar
• Tung R, Novel pyrimidinecarboxamide derivatives. USPTO Application 20130109660. 2013.
   Google Scholar
• Tung RD. Heterocyclic kinase inhibitors. USPTO Application 20130095100. 2013.
   Google Scholar
• Liu JF, Tung R, Harbeson SL. Pyrazinoisoquinoline compounds. USPTO Application 20130029997. 2013.
   Google Scholar
• Tung RD, Masse CE. Substituted derivatives of bicyclic [4.3.0] heteroaryl compounds. USPTO Application 20120295925. 2012.
   Google Scholar
• Masse CE, Harbeson SL, Tung RD. Prostacyclin derivatives. USPTO Application 20120270934. 2012.
   Google Scholar
• Tung RD, Liu JF, Harbeson SL. Substituted xanthine derivatives. USPTO Application 20120202830. 2012.
   Google Scholar
• Liu JF, Tung R, Harbeson SL. Pyrazinoisoquinoline compounds. USPTO Application 20120149709. 2012,
   Google Scholar
• Liu JF, Persichetti RA. Deuterated fingolimod. USPTO Application 20120141513. 2012.
   Google Scholar
• Sommer A, Zhang C, Carter J, et al. Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2. USPTO Application 20170087147. 2017.
   Google Scholar
• Stamler D. Benzoquinoline inhibitors of vesicular monoamine transporter 2. USPTO Application 20160346270. 2016.
   Google Scholar
• Sommer A, Zhang C, Carter J, et al. Novel pharmaceutical formulations. USPTO Application 20160346200. 2016.
   Google Scholar
• Stamler D, Huang MF. Methods for the treatment of abnormal involuntary movement disorders. USPTO Application 20160287574. 2016.
   Google Scholar
• Sommer A, Zhang C, Carter J, et al. Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2. USPTO Application 20160235733. 2016.
   Google Scholar
• Sommer A, Zhang C, Carter J, et al. Formulations phrmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2. USPTO Application 20160222008. 2016.
   Google Scholar
• Zhang C, Benzoquinolone inhibitors of vmat2. USPTO Application 20160207917. 2016.
   Google Scholar
• Sommer A, Zhang C. Benzoquinolone inhibitors of vmat2. USPTO Application 20160068526. 2016.
   Google Scholar
• Sommer A, Zhang C, Carter J, et al., Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2. USPTO Application 20150004231. 2015.
   Google Scholar
• Sommer A, Zhang C, Carter J, et al. Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2. USPTO Application 20140341994 2014.
   Google Scholar
• Sommer A, Zhang C, Carter J, et al. Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2. USPTO Application 20140336386. 2014.
   Google Scholar
• Gant TG, Zhang C, Shahbaz M. Benzoquinolone inhibitors of vmat2. USPTO Application 20120003330. 2012.
   Google Scholar
• Rao T, Zhang C. Benzazepine inhibitors of gamma-secretase. USPTO Application 20110306596. 2011.
   Google Scholar
• Rao T, Zhang C. 3,4-methylenedioxyphenyl inhibitors of gaba aminotransferase and/or gaba reuptake transporter inhibitor, USPTO Application 20110257260. 2011.
   Google Scholar
• Zhang C. Piperidine modulators of dopamine receptor. USPTO Application 20110206782. 2011.
   Google Scholar
• Gant TG, Sarshar S, Zhang C. Morphinan modulators of nmda receptors, sigma1 receptors, sigma2 receptors, and/or a3b4 nicotinic receptors. USPTO Application 20110206780. 2011.
   Google Scholar
• Zhang C, Sommer A. Trimethoxyphenyl inhibitors of tyrosine kinase. USPTO Application 20110206661. 2011.
   Google Scholar
• Rao T, Zhang C. 4,6-diaminopyrimidine stimulators of soluble guanylate cyclase. USPTO Application 20110201626. 2011.
   Google Scholar
• Zhang C, Quinoline inhibitors of tyrosine kinase. USPTO Application 20110195066. 2011.
   Google Scholar
• DeWitt S, Jacques V, Van der Ploeg L. Methods of treating neurological, metabolic, and other disorders using enantiopure deuterium-enriched pioglitazone. USPTO Application 20160331737. 2016.
   Google Scholar
• DeWitt S. 3-(substituted-4-oxoquinazolin-3(4h)-yl)-3-deutero-piperidine-2,6-dione derivatives and compositions comprising and methods of using the same. USPTO Application 20140288101. 2014.
   Google Scholar
• DeWitt S. 5-deutero-2,4-thiazolidinedione derivatives and compositions comprising and methods of using the same. USPTO Application 20140275180. 2014.
   Google Scholar
• Czarnik AW. Deuterium-enriched pioglitazone. USPTO Application 20140243377. 2014.
   Google Scholar
• Czarnik AW. Deuterium-enriched prasugrel. USPTO Application 20140329851. 2014.
   Google Scholar
• DeWitt S. 3-deutero-pomalidomide. USPTO Application 20120302605. 2012.
   Google Scholar
• DeWitt S. 2,6-dioxo-3-deutero-piperdin-3-yl-isoindoline compounds. USPTO Application 20120252844. 2012.
   Google Scholar
• Czarnik AW. Deuterium-enriched ruboxistaurin. USPTO Application 20120136037. 2012.
   Google Scholar
• Czarnik AW. Deuterium-enriched meropenem. USPTO Application 20120122833. 2012.
   Google Scholar
• Czarnik AW. Deuterium-enriched ixabepilone. USPTO Application 20120035227. 2012.
   Google Scholar
• Czarnik AW. Deuterium-enriched dasatinib. USPTO Application 20120015956. 2012.
   Google Scholar
• Czarnik AW. Deuterium-enriched alogliptin. USPTO Application 20110312983. 2011.
   Google Scholar
• Czarnik AW. Deuterium-enriched tolterodine. USPTO Application 20110281952. 2011.
   Google Scholar
• Czarnik AW. Deuterium-enriched doripenem. USPTO Application 20110281927. 2011.
   Google Scholar
• Czarnik AW. Deuterium-enriched dapoxetine. USPTO Application 20110201690. 2011.
   Google Scholar
• Gant TG, Shahbaz MM. Benzoquinoline inhibitors of vesicular monoamine transporter 2. 2013. USPTO 8524733.
   Google Scholar
• Katsnelson A. Heavy drugs draw heavy interest from pharma backers. Nat Med. 2013;19(6):656.
   PubMed Web of Science ®Google Scholar
• El-Gamal Y, Samuel EM, Siddoway PD. The new battlefield: one year of inter partes review under the America invents act. AIPLA QJ. 2014;42:39.
   Google Scholar
• Gant TG, Sarshar S. Substituted phenethylamines with serotoninergic and/or norepinephrinergic activity. USPTO 7456317. 2008.
   Google Scholar
• Fogelman SM,  Schmider J,  Venkatakrishnan K, et al. O-and N-demethylation of venlafaxine in vitro by human liver microsomes and by microsomes from cDNA-transfected cells: effect of metabolic inhibitors and SSRI antidepressants. Neuropsychopharmacology. 1999;20(5):480–490.
   PubMed Web of Science ®Google Scholar
• Miwa GT, Lu AY. Kinetic isotope effects and ‘metabolic switching’in cytochrome P450‐catalyzed reactions. Bioessays. 1987;7(5):215–219.
   PubMed Web of Science ®Google Scholar
• Silverman IR, Liu JF, Morgan AJ, et al. Deuterated derivatives of ruxolitinib. USPTO 9249149. 2016.
   Google Scholar
• Shilling AD, Nedza FM, Emm T, et al. Metabolism, excretion, and pharmacokinetics of [14C] INCB018424, a selective Janus tyrosine kinase 1/2 inhibitor, in humans. Drug Metab Dispos. 2010;38(11):2023–2031.
   PubMed Web of Science ®Google Scholar
• Rodgers JD, Shepard S. Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors. US Patent 7598257. 2009.
   Google Scholar
• Rodgers JD, Shepard S. Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as janus kinase inhibitors. USPTO 9,662,335. 2017.
   Google Scholar
• Lowe J, Benzophenones and sulfones as inhibitors of glycine uptake. USPTO Application 20020052401. 2002.
   Google Scholar
• Yeadon M, Watson J, Armstrong R. Combination of an adenosine A2A-receptor agonist and tiotropium or a derivative thereof for treating obstructive airways and other inflammatory diseases. USPTO Application 20030013675. 2003.
   Google Scholar
• Fu JM. Arylsulphonyl substituted-tetrahydro-and hexahydro-carbazoles. USPTO Application 20040162332. 2004.
   Google Scholar
• Kowala M, Pharmaceutical compositions including an ether and selective COX-2 inhibitor and methods for using such. USPTO Application 20050004196. 2005.
   Google Scholar
• Eggenweiler HM, Wolf M. Pyridazine derivatives. USPTO Application 20050176714. 2005.
   Google Scholar
• Guzi T, Paruch K, Dwyer M. Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors. USPTO Application 20060040958. 2006.
   Google Scholar
• Eatherton A. Pyrimidine derivatives and their use as CB2 modulators. USPTO Application 20060293354. 2006.
   Google Scholar
• Branch C, Johnson C, Nash D, et al. N-aroyl piperazine derivatives as orexin receptor antagonists. USPTO Application 20070167457. 2007.
   Google Scholar
• Folkes A, Shuttleworth S, Oxenford S, et al. Phosphoinositide 3-kinase inhibitor compounds and methods of use. USPTO Application 20080039459. 2008.
   Google Scholar
• Chen H, Song J, Vernier JM, et al. 1,4 diamino bicyclic retigabine analogues as potassium channel modulators. USPTO Application 20080234334. 2008.
   Google Scholar
• Andersen NH, Bowman J, Erwin A, et al. Antibacterial agents. USPTO Application 20080269221. 2008.
   Google Scholar
• Castanedo GM, Gunzer JL, Malesky K, et al. Thiazolopyrimidine p13k inhibitor compounds and methods of use. USPTO Application 20090118275. 2009.
   Google Scholar
• Pettus LH, Tasker A, Xu S, et al. Pyrazolo-pyridinone derivatives and methods of use. USPTO Application 20090137582. 2009.
   Google Scholar
• Grahames C, Mallinder P, McIntosh F, et al. Assays for Allosteric Modulators of G-Protein Coupled Receptors (GPCRs). USPTO Application 20090305321. 2009.
   Google Scholar
• Putnam AMAH, Knudsen N, Norman T, et al. Modified Bovine G-CSF Polypeptides And Their Uses. USPTO Application 20100035812. 2010.
   Google Scholar
• Vasudevan A, Brown BS, Keddy RG, et al. Compounds useful as inhibitors of protein kinases. USPTO Application 20100035919. 2010.
   Google Scholar
• Pracitto R, Kadow JF, Bender JA, et al. Compounds for the Treatment of Hepatitis C. USPTO Application 20100063068. 2010.
   Google Scholar
• Franklin R, Golding BT, Tyson RG. Novel dicarboxylic acid linked amino acid and peptide prodrugs of opioids and uses thereof. USPTO Application 20100286186. 2010.
   Google Scholar
• Koltun D, Parkhill E, Zablocki J. Substituted heterocyclic compounds. USPTO Application 20100113461. 2010.
   Google Scholar
• LundquistJT, Mahaney PE, Kim CY, et al. 1,2,3,6-tetrahydroazepino[4,5-b]indole-5-carboxylate nuclear receptor inhibitors. USPTO Application 20110039824. 2011.
   Google Scholar
• ArikawaY, Dong Q, Feher V, et al. Fused heteroaromatic pyrrolidinones. USPTO Application 20110152273. 2011.
   Google Scholar
• Nguyen PX, Heidelbaugh TM. Novel compounds as receptor modulators with therapeutic utility. USPTO Application 20110152241. 2011.
   Google Scholar
• Otsubo K, Ochi Y, Nakai M, et al. Pharmaceutical agent comprising quinolone compound. USPTO Application 20110251180. 2011.
   Google Scholar
• FollmannM, Stasch JP, Redlich G, et al. Substituted 5-fluoro-1H-pyrazolopyridines and their use. USPTO Application 20120022084. 2012.
   Google Scholar
• Tutino A, Lai M, Etter JB. Pharmaceutical compositions of cytidine analogs and methods of use thereof. USPTO Application 20120196823. 2012.
   Google Scholar
• Piryatinsky V, Laxer A. Deuterated n-ethyl-n-phenyl-1,2-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide, salts and uses thereof. USPTO Application 20140051723. 2014.
   Google Scholar
• Atzrodt J, Derdau V, Holla W, et al. Process for the preparation of deuterated compounds containing n-alkyl groups. USPTO Application 20140081019. 2014.
   Google Scholar
• Wang X, Spear K, Fulp A, et al. Polycyclic thiazoles as potassium ion channel modulators. USPTO Application 20050227989. 2005.
   Google Scholar
• Lee WC, Carter MB, Chuaqui C, et al. Substituted Pyrazalones. USPTO Application 20100056505. 2010
   Google Scholar
• Nakayama K, Sugita K, Setoguchi M, et al. Morpholinopurine derivatives. USPTO Application 20100130492. 2010.
   Google Scholar
• Gong Y, Zinser HB. Process for the preparation of sulfamide derivatives. USPTO Application 20130085176. 2013.
   Google Scholar
• DiMasi JA, Grabowski HG, Hansen RW. Innovation in the pharmaceutical industry: new estimates of R&D costs. J Health Econ. 2016;47:20–33.
   PubMed Web of Science ®Google Scholar